Biomarin Pharmaceutical (BMRN) Received Buy By Canaccord Genuity with $101 Target; 11 Analysts Bullish Rentokil Initial plc (LON:RTO)

Rentokil Initial plc (LON:RTO) Logo

Analysts at Canaccord Genuity has initiated coverage on shares of Biomarin Pharmaceutical (NASDAQ:BMRN) in a a research note shared with investors on 16 May. The financial firm set a Buy rating on the $15.67 billion market cap company.

Among 15 analysts covering Rentokil Initial PLC (LON:RTO), 11 have Buy rating, 1 Sell and 3 Hold. Therefore 73% are positive. Rentokil Initial PLC had 120 analyst reports since July 29, 2015 according to SRatingsIntel. On Thursday, July 23 the stock rating was maintained by AlphaValue with “Buy”. The firm has “Hold” rating by Peel Hunt given on Thursday, November 5. The stock of Rentokil Initial plc (LON:RTO) earned “Buy” rating by AlphaValue on Wednesday, September 23. The firm earned “Underweight” rating on Friday, July 29 by JP Morgan. JP Morgan maintained the stock with “Underweight” rating in Thursday, April 20 report. The stock of Rentokil Initial plc (LON:RTO) has “Add” rating given on Thursday, March 10 by AlphaValue. Deutsche Bank maintained the shares of RTO in report on Tuesday, February 13 with “Buy” rating. As per Thursday, January 4, the company rating was maintained by Peel Hunt. The company was maintained on Monday, November 13 by Peel Hunt. AlphaValue downgraded the stock to “Add” rating in Tuesday, February 16 report. See Rentokil Initial plc (LON:RTO) latest ratings:

16/05/2018 Broker: Peel Hunt Rating: Add Old Target: GBX 343.00 Maintain
27/04/2018 Broker: BNP Paribas Rating: Outperform Old Target: GBX 315.00 New Target: GBX 330.00 Maintain
19/04/2018 Broker: Peel Hunt Rating: Add Old Target: GBX 343.00 New Target: GBX 343.00 Maintain
16/04/2018 Broker: Deutsche Bank Rating: Hold Old Target: GBX 335.00 New Target: GBX 310.00 Downgrade
13/04/2018 Broker: RBC Capital Markets Rating: Outperform Old Target: GBX 350.00 New Target: GBX 350.00 Maintain
06/04/2018 Broker: Deutsche Bank Rating: Buy Old Target: GBX 335.00 Maintain
14/03/2018 Broker: Numis Securities Rating: Add Old Target: GBX 315.00 New Target: GBX 315.00 Maintain
05/03/2018 Broker: Credit Suisse Rating: Outperform Old Target: GBX 330.00 New Target: GBX 330.00 Maintain
05/03/2018 Broker: RBC Capital Markets Rating: Outperform Old Target: GBX 350.00 New Target: GBX 350.00 Maintain
02/03/2018 Broker: Jefferies Rating: Buy Old Target: GBX 335.00 New Target: GBX 340.00 Upgrade

Rentokil Initial plc, through its subsidiaries, provides route services in North America, the United Kingdom, rest of Europe, Asia, and rest of world. The company has market cap of 5.90 billion GBP. It offers a range of pest control services from rodents to flying insects, as well as to other forms of wildlife management for commercial and residential customers. It has a 8.71 P/E ratio. The firm also provides hygiene services, including the provision and maintenance of products, such as air fresheners, sanitizers, feminine hygiene units, hand dryers, paper and linen towel dispensers, soap dispensers, and floor protection mats.

The stock increased 1.01% or GBX 3.2 during the last trading session, reaching GBX 321.4. About 1.01 million shares traded. Rentokil Initial plc (LON:RTO) has 0.00% since May 16, 2017 and is . It has underperformed by 11.55% the S&P500.

The stock decreased 0.94% or $0.84 during the last trading session, reaching $88.7. About 707,834 shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has declined 11.55% since May 16, 2017 and is downtrending. It has underperformed by 23.10% the S&P500.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company has market cap of $15.67 billion. The Company’s commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria , an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. It currently has negative earnings. The firm also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB.

Among 27 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 21 have Buy rating, 0 Sell and 6 Hold. Therefore 78% are positive. BioMarin Pharmaceutical has $175 highest and $89 lowest target. $118.08’s average target is 33.12% above currents $88.7 stock price. BioMarin Pharmaceutical had 91 analyst reports since August 5, 2015 according to SRatingsIntel. Stifel Nicolaus maintained it with “Buy” rating and $102 target in Friday, February 23 report. BMO Capital Markets initiated the shares of BMRN in report on Thursday, April 7 with “Outperform” rating. The rating was maintained by SunTrust with “Buy” on Thursday, October 19. The stock has “Outperform” rating by Raymond James on Tuesday, September 1. The firm has “Hold” rating given on Wednesday, November 15 by Wedbush. The rating was maintained by Robert W. Baird with “Buy” on Tuesday, October 3. The rating was maintained by Deutsche Bank on Thursday, July 13 with “Buy”. Cowen & Co maintained it with “Buy” rating and $150.0 target in Wednesday, October 18 report. On Wednesday, November 18 the stock rating was initiated by Goldman Sachs with “Buy”. Wedbush maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Friday, April 20 with “Buy” rating.

More notable recent BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) news were published by: Streetinsider.com which released: “Viking Global’s 13F Shows New Stakes in Alibaba (BABA), BioMarin (BMRN) and Western Digital (WDC), Increase in …” on May 15, 2018, also Streetinsider.com with their article: “BioMarin Pharma (BMRN) Reports First Patient Dosed in Phase 1/2 Study Evaluating Valoctocogene Roxaparvovec …” published on May 15, 2018, Gurufocus.com published: “Andreas Halvorsen Buys Alibaba, United States Steel in 1st Quarter” on May 15, 2018. More interesting news about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) were released by: Fool.com and their article: “BioMarin Cruises While It Waits on Seventh Approval” published on April 27, 2018 as well as Prnewswire.com‘s news article titled: “BioMarin Announces First Patient Dosed in Phase 1/2 Study Evaluating Valoctocogene Roxaparvovec Gene Therapy …” with publication date: May 15, 2018.

Since December 14, 2017, it had 0 buys, and 21 selling transactions for $14.93 million activity. Another trade for 10,000 shares valued at $846,285 was sold by BIENAIME JEAN JACQUES. The insider Ajer Jeffrey Robert sold $169,774. 3,818 shares were sold by Davis George Eric, worth $320,254 on Friday, March 16. Another trade for 3,750 shares valued at $318,750 was sold by LAWLIS V BRYAN. $1.34M worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was sold by FUCHS HENRY J. 11,059 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares with value of $908,497 were sold by SPIEGELMAN DANIEL K. $71,116 worth of stock was sold by HERON ELAINE J on Thursday, December 14.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Chart